You are here » Home » Companies » Company Overview » Sigachi Industries Ltd

Sigachi Industries Ltd.

BSE: 543389 Sector: Industrials
NSE: SIGACHI ISIN Code: INE0D0K01014
BSE 00:00 | 26 Nov 491.90 -24.70
(-4.78%)
OPEN

493.00

HIGH

510.00

LOW

490.80

NSE 00:00 | 26 Nov 489.60 -23.35
(-4.55%)
OPEN

490.80

HIGH

509.70

LOW

487.35

OPEN 493.00
PREVIOUS CLOSE 516.60
VOLUME 62183
52-Week high 648.00
52-Week low 490.60
P/E 52.05
Mkt Cap.(Rs cr) 1,512
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 493.00
CLOSE 516.60
VOLUME 62183
52-Week high 648.00
52-Week low 490.60
P/E 52.05
Mkt Cap.(Rs cr) 1,512
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Sigachi Industries Ltd. (SIGACHI) - Chairman Speech

Company chairman speech

For a business that has sailed through evolving markets tor over the last threedecades the ever-changing industry scenarios become nothing but challenges to overcome.We at Sigachi strive to be entrepreneurial innovative consistent and adaptive withtime and this in turn has served usgreat all theseyears."

Dear Valued Shareholders

On behalf of the Board of Directors I am pleased to presenttoyou Sigachi IndustriesLimited's Annual Report for the financial year ended 31 March 2020. Amid an uncertainglobal environment and ever-changing industry dynamics our performance this year has beencommendable not only in financial terms but also in terms of what we achieved for ourcustomersemployees and shareholders.

India being a major producer and exporter of generic drugs and with measures by thegovernment to boost local production a significant opportunity lies ahead for Pharmaexcipient companies in India with large manufacturing units. We at Sigachi have investedin relevant expertise and capacity across our three units situated in Hyderabad Dahej andJhagadia to cater to the increasi ng demand for higher potency and niche drugs.

Secured supply chains high volume production and a dedicated R&D team has helpedSigachi capture a significant share of the ever-changing global marketplace. Fora businessthat has sailed through evolving markets for over the last three decades theever-changing industry scenarios become nothing but challenges to overcome. We at Sigachistrive to be entrepreneurial innovative consistent and adaptive with time and this inturn has served us great all theseyears.

Owing to the increase in demand for oral solid pharmaceutical drugs and emergence ofnovel therapeutics emerging markets are growing in importance for pharmaceuticalexcipient market. There is enormous potential for pharmaceutical excipients and this issubstantiated with growing healthcare expenditures rising income levels and improvinghealth awareness amongst people. Excipient quality plays a vital role in assuring safetyquality and efficacy of dosage forms. With our highly dedicated R &D capabilities weremain to be the manufacturer of choice for excipients with highest quality standardsacross ou r products.'

I would like to extend my sincere gratitude towards each and every member of theSigachi Family for their relentless efforts and contributions during the nation-widelockdown. Our teams have demonstrated a strong sense of responsibility and have helped uscontinue with business as usual despite all the odds of the situation. With a team ascommitted as this I am confidentthat this event is unlikely to have any significa ntimpact on our business.

On behalf of the Board I would like to assure our shareholders customers suppliersbankers business partners and our employees that their trust and confidence on us willonly be strengthened in the coming years and we look forward to your continued support ina greater measure in the years ahead.

Best Regards.
Rabindra Prasad Sfnha
Chairman of the Company

.